Ann: Immutep to present TACTI-002 data at German Cancer Congress, page-6

Significance of more mature data in NSCLC:-
Standard of care - PD-L1 positive patients - chemo 15 months median survival benefit.
IO/IO (Opdivo/Yervov) PD-L1 positive patients - 17 months median survival benefit. 21% ORR. (European application withdrawn)
IO (Keytruda mono) PD-L1 positive patients - survival benefit 19% v chemo (Keytruda approved only in >50% PD-L1 expression)
IO/IO (Keytruda/Efti) PD-L1 'all comers' - medial survival benefit unknown - as yet. ORR 41% (interim small population P2 data).
If data continues to be positive and there is a clear clinical benefit of Keytruda and Efti (with less toxiticy) combo could potentially be an alternative first line treatment for NSCLC - irrespective of PD-L1 patient status, thus opening up an additional market population for Keytruda, BUT only when in a combo with Efti.....